{"analyses":[{"groupIds":["OG000","OG001","OG002","OG003"],"nonInferiorityType":"OTHER","pValue":"0.0731","statisticalComment":"1-factor ANOVA of log-transformed, dose-normalized data (factor = dose)","statisticalMethod":"ANOVA"},{"ciLowerLimit":"0.784","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.110","groupIds":["OG002","OG003"],"nonInferiorityType":"OTHER","paramType":"pairwise geometric mean ratio (GMR)","paramValue":"0.933"},{"ciLowerLimit":"0.908","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.271","groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"pairwise GMR","paramValue":"1.074"},{"ciLowerLimit":"1.034","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.463","groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","paramType":"pairwise GMR","paramValue":"1.230"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.30","value":"763"},{"groupId":"OG001","spread":"0.26","value":"1310"},{"groupId":"OG002","spread":"0.30","value":"1420"},{"groupId":"OG003","spread":"0.33","value":"1990"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"description":"Cmax was defined as the maximum observed concentration of INCB001158.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"INCB001158 was administered orally at 50 milligrams (mg) twice daily (BID) in participants with advanced/metastatic solid tumors.","id":"OG000","title":"Part 1A: INCB001158 50 mg"},{"description":"INCB001158 was administered orally at 75 mg BID in participants with advanced/metastatic solid tumors.","id":"OG001","title":"Part 1A: INCB001158 75 mg"},{"description":"INCB001158 was administered orally at 100 mg BID in participants with advanced/metastatic solid tumors.","id":"OG002","title":"Part 1A: INCB001158 100 mg"},{"description":"INCB001158 was administered orally at 150 mg BID in participants with advanced/metastatic solid tumors.","id":"OG003","title":"Part 1A: INCB001158 150 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) Population: all participants who received at least 1 dose of INCB001158 or pembrolizumab and contributed at least 1 PK sample","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: predose; 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post-dose","title":"Cmax of INCB001158 Following Single Escalating Doses for Part 1A","type":"SECONDARY","unitOfMeasure":"nanograms per milliliter (ng/mL)"}